Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire
- PMID: 17408073
Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire
Abstract
Assessment of quality of life (QOL) is of crucial importance when assigning palliative radiotherapy of brain metastases in cancer patients.
Aim: To investigate the influence of whole brain radiotherapy on brain symptoms in patients with cerebral metastases; to evaluate their quality of life before and after radiation therapy using the EORTC-QOL-C30 questionnaire, as well as its influence on patients' survival.
Patients and methods: Sixty-five patients with various locations of the primary tumor and brain metastases were included in this study. All of them underwent radiotherapy with cobalt unit. The realized dose of the whole brain was above 30 Gy: 10 x 3 Gy or 15 x 2 Gy. The patients filled in the EORTC-QOL-C30 questionnaire before radiation, at the end of the radiotherapeutic course and a month after it. Clinical characteristics of patients before and after radiotherapy were compared and assessed. All patients were treated with radiotherapy and concurrent corticosteroid treatment.
Results: The mean age of the patients was 53 +/- 7.8 years and the median survival was 6.6 months for lung cancer patients and 9.8 months for breast cancer patients. Each EORTC-QOL-C30 questionnaire assessed the patients in three main aspects: functional aspects, general symptoms and global health. Improvement was reported (p < 0.001) for functional indicators and health related quality of life (HRQOL). Several symptoms did not change significantly--financial difficulties, dyspnea and diarrhea.
Conclusions: Whole brain radiation of cancer patients with cerebral metastases is very well tolerated. Side effects are frequently met and can be compensated by applying steroids. The assessment of quality of life gives information on patients' improvement which is more substantial in functioning, symptoms and global health. This study is a precondition for future investigations of the effect of whole brain radiation on cancer patients' quality of life.
Similar articles
-
Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1238-45. doi: 10.1016/j.ijrobp.2011.09.025. Epub 2011 Dec 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 22172909
-
Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort.Ann Palliat Med. 2017 Aug;6(Suppl 1):S65-S70. doi: 10.21037/apm.2017.04.06. Epub 2017 May 17. Ann Palliat Med. 2017. PMID: 28595442
-
Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.J Neurosurg. 2018 Jul;129(1):71-83. doi: 10.3171/2017.2.JNS161659. Epub 2017 Aug 18. J Neurosurg. 2018. PMID: 28820304
-
The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review.Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):693-700. doi: 10.1586/erp.11.66. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098285 Review.
-
Radiotherapy for palliation of symptoms in incurable cancer.Curr Probl Cancer. 1997 May-Jun;21(3):129-83. doi: 10.1016/s0147-0272(97)80004-9. Curr Probl Cancer. 1997. PMID: 9202888 Review.
Cited by
-
Quality of life and radiotherapy in brain metastasis patients.Rep Pract Oncol Radiother. 2012 Sep 5;17(5):281-7. doi: 10.1016/j.rpor.2012.08.003. eCollection 2012 Sep. Rep Pract Oncol Radiother. 2012. PMID: 24669309 Free PMC article.
-
Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases.Med Pharm Rep. 2019 Jan;92(1):43-51. doi: 10.15386/cjmed-1040. Epub 2019 Jan 15. Med Pharm Rep. 2019. PMID: 30957086 Free PMC article.
-
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.Transl Lung Cancer Res. 2024 Dec 31;13(12):3289-3302. doi: 10.21037/tlcr-24-481. Epub 2024 Dec 27. Transl Lung Cancer Res. 2024. PMID: 39830774 Free PMC article.
-
Quality of life in brain metastases radiation trials: a literature review.Curr Oncol. 2008 Oct;15(5):25-45. doi: 10.3747/co.v15i5.290. Curr Oncol. 2008. PMID: 19008990 Free PMC article.
-
Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.Curr Neurol Neurosci Rep. 2013 Jul;13(7):359. doi: 10.1007/s11910-013-0359-y. Curr Neurol Neurosci Rep. 2013. PMID: 23666388 Review.
MeSH terms
LinkOut - more resources
Medical
Miscellaneous